Anest Iwata reports mixed Q2 results amid market challenges

Anest Iwata Corporation reported Q2 FY2026 results with sales of 26,325 million yen, a 2.7% decrease year-over-year from 27,060 million yen. Operating profit also fell by 15.2% to 2,511 million yen from 2,962 million yen in the previous year, primarily due to decreased sales and increased selling, general, and administrative expenses, despite an improved cost of sales ratio.

Despite the decline in sales and operating profit, ordinary profit and net profit attributable to parent company shareholders exceeded initial forecasts. Ordinary profit was 3,296 million yen (down 4.8%), and net profit attributable to parent company shareholders was 2,160 million yen (down 1.5%), largely benefiting from favorable foreign exchange fluctuations. The company plans an interim dividend of 41 yen per share.

Looking ahead to the full year ending March 2026, Anest Iwata maintains its previous forecast, aiming for sales of 58,000 million yen and operating profit of 5,550 million yen. The company is developing a master plan for Vision 2035, set to be disclosed in May 2026, to achieve its long-term goals.